Medtronic's drug-coated balloon for dialysis fistulas clears study

Medtronic HQ
The IN.PACT AV balloon is being developed for the U.S., Japan and New Zealand, in different sizes compared to Medtronic’s paclitaxel-coated IN.PACT Admiral device. (Medtronic)

A new version of Medtronic’s drug-coated balloon, designed specifically to help reopen the collapsing fistulas used by patients as access ports for dialysis treatments, has met its primary endpoints in its first large study.  

The medtech giant’s IN.PACT AV balloon is being developed for the U.S. market, as well as Japan and New Zealand, in different sizes compared to Medtronic’s paclitaxel-coated IN.PACT Admiral device.  

The Admiral balloon previously received a CE mark clearing it for use in arteriovenous fistulas in January 2016, and Medtronic currently has no plans to replace that product in the European market, according to a company spokesperson.  

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

IN.PACT AV’s clinical study enrolled 330 patients who had been receiving hemodialysis treatments for an average of 4.3 years. Compared to traditional percutaneous transluminal angioplasty, patients who received treatment with the drug-coated balloon needed 56% fewer reinterventions to maintain their access fistula over 210 days.  

RELATED: Concept Medical racks up breakthrough designations for its drug-coated balloons, now for clearing dialysis fistulas 

According to Medtronic, narrowing fistulas can interrupt critical dialysis treatments, with end-stage renal disease patients having to undergo one to three maintenance procedures each year. 

In the study, the target vessel remained open in 86.1% of treated patients after 180 days, compared to 68.9% in the control group. After 210 days, the IN.PACT arm had a patency rate of 81.4%, versus 68.9% with traditional angioplasty, while safety data were similar. The results were presented at the annual meeting of the Cardiovascular and Interventional Radiology Society of Europe in Barcelona, Spain.

Suggested Articles

The facility, to be based in the new life sciences center One Discovery Square, is expected to open before the end of this year.

The FDA announced plans to join two collaborative communities focused on real-world evidence and ophthalmic imaging.

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.